论文部分内容阅读
Lehman Brothers分析预测,到10年末(即2000年)有6种药物每年销售额将超过200亿美元,其中包括2种生物技术药物。预测在销售额超过5亿美元的65种药物中默克公司占7个、辉瑞6个、葛兰素5个。 Lehman Brothers最近报道 2000年“爆炸性”药物名单(见 Scrip 1991;1652:27)。该名单列出到2000年有51种药物的销售额将超过5亿美元,其中有3个药物的销售额有希望超过200亿美元。分析家相信,到2000年以下药物将超过200亿美元的“爆炸性”药物。
Lehman Brothers analysis predicts that by the end of 10 (ie 2000) six drugs will have annual sales of more than 20 billion U.S. dollars, including two biotech drugs. It is estimated that Merck will account for 7 of the 65 drugs with sales of more than 500 million U.S. dollars, 6 for Pfizer and 5 for Glaxo. Lehman Brothers recently reported the list of “explosive” drugs of 2000 (see Scrip 1991; 1652: 27). The list lists 51 types of drugs that will have sales of more than 500 million U.S. dollars by the year 2000, of which three have promising sales of more than 20 billion U.S. dollars. Analysts believe that by the year 2000 drugs will exceed $ 20 billion in “explosive” drugs.